Jeito Capital leads $65 million round in ReproNovo

Jeito Capital led a $65 million Series A investment in ReproNovo , a biopharma company developing treatments for reproductive medicine and women’s health. AXA IM Alts and M Ventures co-led the round, joined by Ysios Capital and ALSA Ventures.

ReproNovo will use the funds to advance two Phase 2 clinical candidates: RPN-001, an oral therapy for male infertility linked to low testosterone, and RPN-002, targeting adenomyosis and embryo implantation success in assisted reproductive technology. The company, founded in 2021, operates out of Switzerland, Denmark, and Spain.